<DOC>
	<DOCNO>NCT02488330</DOCNO>
	<brief_summary>This extension study provide continue onartuzumab and/or parent trial ( P-trial ) designate control treatments participant cancer previously enrol company-sponsored onartuzumab P-trial derive benefit , assess responsible investigator , therapy administer P-trial . The study also collect safety data regard administration continue onartuzumab therapy .</brief_summary>
	<brief_title>An Extension Study Onartuzumab Participants With Solid Tumors Study Treatment Previously Enrolled Company Sponsored Study</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Enrolled receive either control treatment onartuzumabbased study treatment eligible Ptrial Has meet treatment discontinuation criterion specify Ptrial protocol time enrollment extension trial ( Etrial ) Ability begin treatment extension ( rollover ) protocol within 15 day follow last day study antecedent protocol For woman postmenopausal ( great equal [ &gt; /= ] 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use single combine nonhormonal contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 180 day last dose study drug For men : agreement remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 180 day last dose study drug agreement refrain donate sperm period Pregnancy lactation intention become pregnant study ( serum pregnancy test require enrollment ) Any nonprotocol anticancer therapy start discontinuation treatment Ptrial start enrollment Etrial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>